Metabolic dysfunction-associated steatotic liver disease (MASLD) has become a widespread and growing global health concern, affecting an estimated one in six people worldwide. There are now 1.3 billion people living with MASLD globally, representing a 143% increase from about 500 million in 1990. The global prevalence rate grew to 14,429 cases per 100,000 people in 2023, a 29% increase from 1990. Projections indicate metabolic liver disease will affect 1.8 billion people worldwide by 2050, driven by rising obesity and blood sugar levels. In the UK, MASLD is the most common liver condition, affecting an estimated one in three British adults, though other estimates suggest around one in five people in the UK have MASLD.
MASLD develops when fat builds up in the liver and is often symptomless, unlike other forms of liver disease that are directly linked to alcohol intake. The condition is triggered by metabolic or lifestyle issues including being overweight, Type 2 diabetes, a poor diet, a high waist measurement, low levels of physical activity, high cholesterol, and high blood pressure. Those most at risk include people who are overweight—particularly with excess fat around the waist—as well as individuals with poor diets or low levels of exercise. MASLD is also more common in individuals with type 2 diabetes, polycystic ovary syndrome, high blood pressure, high cholesterol, and adults over 50.
A new study has uncovered a critical link between binge drinking and severe liver damage in MASLD patients. The research found that even one heavy drinking session a month could triple the risk of severe liver damage for people with MASLD. In the study, binge drinking was defined as four or more drinks in a day for women, and five or more for men, at least once a month. The study analysed data from more than 8,000 adults between 2017 and 2023, revealing that younger adults and men were more likely to report binge drinking. More than half of participants reported occasional binge drinking, and nearly 16% of those with MASLD fell into this category. When comparing individuals of similar age, sex, and average weekly alcohol intake, those who engaged in occasional binge drinking had nearly three times the odds of developing advanced liver fibrosis.
Demographic patterns show MASLD was more common in men than women and had the highest prevalence rates in older adults aged between 80 and 84. However, the largest number of people affected were younger—around the ages of 35 to 39 in men and 55 to 59 in women. High blood sugar was the leading driver of MASLD-related health problems globally, followed by high BMI and smoking. Some regions, including north Africa and the Middle East, had disproportionately higher rates of MASLD compared with other regions.
Country-specific trends reveal sharp increases in MASLD prevalence over recent decades. In the UK, the prevalence rate increased by a third—33%—between 1990 and 2023, the biggest rise in western Europe. During the same period, the prevalence rate grew by 30% in Australia and 22% in the United States.
Health impacts of MASLD are substantial, though the study found that although more people were developing the disease, the overall impact on health—measured in years lost because of illness or death—was stable. Despite this stability in population-level metrics, the growing number of cases still means that many people are at risk of developing serious complications such as liver cirrhosis or cancer in the future.
Treatment approaches for MASLD focus primarily on lifestyle modifications, as the condition is often linked to being overweight and can usually be treated with lifestyle changes. A significant challenge is that MASLD does not usually cause any symptoms, and many people have the condition without realising. Liver disease often develops silently, with no obvious symptoms in its early stages.
Expert commentary highlights shifting perspectives on risk assessment for liver disease. Traditionally, physicians have tended to look at the total amount of alcohol consumed, not how it is consumed, when determining the risk to the liver. Research suggests the public needs to be much more aware of the danger of occasional heavy drinking and should avoid it even if they drink moderately the rest of the time.
Context on the contradictions in UK prevalence estimates reveals uncertainty about the true scale of the problem. Some major media reports indicate MASLD affects an estimated one in three British adults, while others suggest around one in five people in the UK are estimated to have MASLD.
The implications of the binge drinking study for public health messaging are substantial, suggesting that current guidelines focusing solely on total weekly alcohol intake may be insufficient. The research indicates that drinking patterns matter significantly for MASLD patients, with binge drinking dramatically increasing fibrosis risk even when total alcohol consumption remains moderate.
Several important unknowns persist regarding effective interventions and disease progression. What specific lifestyle changes are most effective for treating MASLD remains unclear. How many people with MASLD progress to serious complications like cirrhosis or cancer is not well quantified.
Additional unknowns concern both biological mechanisms and geographic patterns. Why the UK has seen the biggest rise in MASLD prevalence in Western Europe remains unexplained. What are the current treatment options beyond lifestyle changes for advanced MASLD is another area requiring research.
In conclusion, the growing global burden of MASLD combined with new evidence about the dangers of binge drinking creates an urgent need for increased awareness and preventive measures. Public health campaigns must address both metabolic risk factors and drinking patterns, particularly for younger adults and men who show higher binge drinking rates.